R
ResVerlogiX
AB - Calgary
BiotechnologyFocus: Small Molecules
ResVerlogiX is a life sciences company focused on Small Molecules.
CardiovascularMetabolic DiseasesInfectious DiseasesNephrologyRare Diseases
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Apabetalone
Pulmonary Arterial HypertensionClinical Trials (1)
NCT03655704Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
Phase 1RVX000222
Fabry DiseaseClinical Trials (1)
NCT03228940Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
Phase 1/2RVX000222
DyslipidemiaClinical Trials (1)
NCT00768274Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
Phase 1/2apabetalone
Kidney Failure, ChronicClinical Trials (1)
NCT03160430A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis
Phase 1/2RVX000222
AtherosclerosisClinical Trials (1)
NCT01058018Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease
Phase 2RVX000222
DyslipidemiaClinical Trials (1)
NCT01863225Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
Phase 2RVX000222
DiabetesClinical Trials (1)
NCT01728467The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes
Phase 2Apabetalone
Pulmonary Arterial HypertensionClinical Trials (1)
NCT04915300Apabetalone for Pulmonary Arterial Hypertension
Phase 2RVX000222
Coronary Artery DiseaseClinical Trials (1)
NCT01067820ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
Phase 2RVX000222
Coronary Artery DiseaseClinical Trials (1)
NCT01423188The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation
Phase 2Apabetalone
COVID-19 InfectionClinical Trials (1)
NCT04894266An Open-Label Study of Apabetalone in Covid Infection
Phase 2/3Apabetalone
Post-Acute COVID-19 SyndromeClinical Trials (1)
NCT06590324A Study of Apabetalone in Subjects With Long -COVID
Phase 2/3Apabetalone
Diabetes Mellitus, Type 2Clinical Trials (1)
NCT02586155Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2001
Portfolio: 13 clinical trials